Prof Goldstein is a leading Oncologist with expertise in clinical and pre-clinical pancreatic cancer (PC). He has co-authored multiple clinical and preclinical studies in therapeutics and has experience in translating preclinical models into clinical studies. His global body of work led to changes in treatment, such as introduction of reimbursed adjuvant chemotherapy for PC, and improved patient outcomes and treatment uptake rates, including use of reimbursed combination chemotherapy in PC. His achievements were recognised by a John Zalcberg OAM Award for Excellence in clinical trials research (2016) and Professor Rob Sutherland AO Make a Difference Award (NSW Premier’s Awards, 2017). He has been a CI on >$33M peer-reviewed grants including:- a current CIA, Cancer Institute NSW (CINSW) Pancreas Translational Program Grant (TPG; $3.75M, 2021-25). He has  co-authored 420 peer reviewed publications (citations = 44235; h-index 88).